Jizhi
Jizhi Li US
Patent application number | Description | Published |
---|---|---|
20100098716 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy. | 04-22-2010 |
20100099145 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy. | 04-22-2010 |
Jizhi Zhang, Arcadia, CA US
Patent application number | Description | Published |
---|---|---|
20100224891 | VERTICALLY STRUCTURED LED BY INTEGRATING NITRIDE SEMICONDUCTORS WITH Zn(Mg,Cd,Be)O(S,Se) AND METHOD FOR MAKING SAME - A light emitting diode (LED) with a vertical structure, including electrical contacts on opposing sides, provides increased brightness. In some embodiments an LED includes a nitride semiconductor light emitting component grown on a sapphire substrate, a Zn(Mg,Cd,Be)O(S,Se) assembly formed on the nitride semiconductor component, and a further Zn(Mg Cd,Be)O(S,Se) assembly bonded on an opposing side of the light emitting component, which is exposed by removing the sapphire substrate. Electrical contacts may be connected to the Zn(Mg,Cd,Be)O(S,Se) assembly and the further Zn(Mg,Cd,Be)O(S,Se) assembly. Herein Zn(Mg,Cd,Be)O(S,Se) is a II-VI semiconductor satisfying a formula Zn | 09-09-2010 |
Jizhi Zhang, Walnut, CA US
Patent application number | Description | Published |
---|---|---|
20120119203 | GROUP IV ELEMENT DOPED P-TYPE Zn(Mg,Cd,Be)O(S,Se) SEMICONDUCTOR - A p-type group II-VI semiconductor may include a group IV element as a dopant. The group II-IV semiconductor may be Zn | 05-17-2012 |
Jizhi Zhao, Shandong Province CN
Patent application number | Description | Published |
---|---|---|
20110010468 | CLOSE-COUPLING SHARED STORAGE ARCHITECTURE OF DOUBLE-WING EXPANDABLE MULTIPROCESSOR - A close-coupling shared storage architecture of double-wing expandable multiprocessor is provided in the close-coupling shared storage architecture with p processors scale, the close-coupling shared storage architecture of double-wing expandable multiprocessor comprises: j processor modules PMs; wherein, each processor module is formed by coupling and cross-jointing i processors Cs, and each processor is directly connected with a node controller NC through only one link; each processor module PM comprises 2 pairing node controllers NCs, and each node controller NC is connected with the processors through m links and is connected with an interconnect network through n links; the interconnect network comprises two groups, and each group comprises k cross switch route chips NRs, each of which has q ports. By adopting the connection method above, the close-coupling shared storage architecture of double-wing expandable multiprocessor is formed. On the premise that the processor scale is kept expandable, the balance between the processor bandwidth and the network bandwidth is achieved, and the lower average delay of the interconnect network is kept simultaneously. | 01-13-2011 |